Physician profile
Guillermo Nava
NPI 1083722524
$1,990.72
in general payments reported to CMS, 2019-2025
15 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $122 · 2021: $115 · 2022: $410 · 2023: $372 · 2024: $123 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $348.76 | 2019-2022 | |
| Boston Scientific Corporation | $324.68 | 2019-2025 | Watchman Flx, Watchman Access System |
| Janssen Pharmaceuticals, INC | $257.18 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $168.16 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $163.25 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $146.64 | 2022-2023 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $108.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $99.95 | 2019-2024 | |
| Lantheus Medical Imaging, INC. | $94.08 | 2023-2024 | Definity |
| Abbott Laboratories | $79.64 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $56.24 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.46 | 2023 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $52.09 | 2023 | Inpefa |
| Heartflow, INC. | $23.35 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Nava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.